Company news
AIM Vaccine Co., Ltd. news in 2026
AIM Vaccine Co., Ltd.'s news releases, calls and decks from 2026, newest first.
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2026
November 3, 2026
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
October 5, 2026
World's First Serum-Free Iterative Rabies Vaccine from AIM Successfully Passes On-Site Registration Inspections and Is Imminent for Launch
February 5, 2026
AIM Vaccine's 20-Valent Pneumococcal Conjugate Vaccine Receives Clinical Approval, Upgraded Iterative Major Product Expected to Seize Domestic Opportunities
January 19, 2026
AIM's Iterative Process High-Efficiency Diploid Rabies Vaccine Completes Phase III Clinical Trials, Efficacy Significantly Higher than Existing Market Products
January 14, 2026